AR037233A1 - Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento - Google Patents

Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento

Info

Publication number
AR037233A1
AR037233A1 ARP020103213A ARP020103213A AR037233A1 AR 037233 A1 AR037233 A1 AR 037233A1 AR P020103213 A ARP020103213 A AR P020103213A AR P020103213 A ARP020103213 A AR P020103213A AR 037233 A1 AR037233 A1 AR 037233A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
alkyl
formula
hydrogen
Prior art date
Application number
ARP020103213A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR037233A1 publication Critical patent/AR037233A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Abstract

Un compuesto piridina aril sustituida que tiene la fórmula (1), o una sal, profármaco o solvato farmacéuticamente aceptable del mismo, en donde: Ar se selecciona entre el grupo que consiste en Ar1, Ar2, Ar3 y Ar4, en donde; Ar1 es de fórmula (2); Ar2 es de fórmula (3); Ar3 es de fórmula (4); Ar5 es de fórmula(5);R1 se selecciona entre el grupo que consiste en un alquilo opcionalmente sustituido, amino, alquiltiol, C(O)R10, SO2R10, OC(O)NH2, 2-imidazolinilo, 2-imidazolilo, 3-pirazolilo, 5-isoxazolilo y 3-(1,2,4)-triazolilo; R2, R3 y R4 se selecciona en forma independiente entre el grupo que consiste en hidrógeno, alquilo, alquenilo o alquinilo opcionalmente sustituido, halógeno, hidroxi, cicloalquilo, ciano, amino, alquilamino, dialquilamino, alcoxi, aminocarbonilo, alquilaminocarbonilo, arilaminocarbonilo, aralquilaminocarbonilo, alquilcarbonilamino, arilcarbonilamino y aralquilcarbonilamino; siempre y cuando que 1) el anillo piridilo no sea 2,6-disustituido con respecto a Ar y R1, o cualquiera de R2-R4 que no es hidrógeno; y 2) cuando Ar es Ar2 o Ar3, entonces R1 es C(O)R10; 3) cuando Ar es Ar4, entonces R1 es aminocarbonilo o un heterocicloalquilaminocarbonilo opcionalmente sustituido; R5, R6, R7 y R8 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, hidroxialquilo, hidroxi, nitro, amino, ciano, amida, carboxialquilo, alcoxialquilo, ureído, acilamino, tiol, aciloxi, azido, alcoxi, carboxi, carbonilamido y alquiltiol; R9 es un alquilo opcionalmente sustituido; R10 se selecciona entre el grupo que consiste en alquilo, alquenilo, alquinilo, OR11, amino, alquilamino, dialquilamino, alquenilamino, dialquilaminoalquenilo, dialquilaminoalquilamino, dialquilaminoalquenilamino, alquilaminoalquenilamino, hidroxiaminoalquenilamino, cicloalquilo, heterocicloalquilo, cicloalquilalquilamino, heterocicloalquilamino, arilo, arilalquilo, arialquenilo, arilalquinilo y arilalquilamino, todos los cuales pueden ser opcionalmente sustituidos, siempre y cuando que R10 no sea OR11 cuando R1 es SO2R10; en donde R11 se selecciona entre el grupo que consiste en hidrógeno, alquilo, opcionalmente sustituido y un metal alcalino; y X es uno de O, S, NH, o CH2 cuando Ar es Ar1; o X es una de O, S, NH, o está ausente (un enlace covalente) cuando Ar es Ar4, con las condiciones de que : 4) cuando Ar es Ar1, X es O, R5, R6 y R7 es cada uno hidrógeno, y R1 es un grupo alquilo, entonces R8 no es un grupo alcoxi opcionalmente sustituido; y 5) cuando Ar es Ar4, y X es O ó está ausente y R1 es aminocarbonilo, entonces R9 no es grupo alquilo de cadena recta opcionalmente monosustituido con halógeno, carboxi, alcoxi, un fenilo opcionalmente sustituido, o un aminocarbonilo opcionalmente sustituido. Además está dirigida a composiciones farmacéuticas y al uso de compuestos de la fórmula (1) para la elaboración de medicamentos para el tratamiento de dano neuronal como consecuencia de isquemia global y focal, para el tratamiento o prevención de condiciones neurodegenerativas tales como esclerosis lateral amiotrófica (ELA) y para el tratamiento, prevención o mejoría tanto de dolor agudo como crónico, como agentes antitinnitus, como anticonvulsivos, y como depresivos antimaníacos, como anestésicos locales, como antiarrítmicos y para el tratamiento o prevención de neuropatía diabética.
ARP020103213A 2001-09-07 2002-08-27 Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento AR037233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31752601P 2001-09-07 2001-09-07

Publications (1)

Publication Number Publication Date
AR037233A1 true AR037233A1 (es) 2004-11-03

Family

ID=23234074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103213A AR037233A1 (es) 2001-09-07 2002-08-27 Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento

Country Status (12)

Country Link
US (3) US7105549B2 (es)
EP (1) EP1432419A1 (es)
JP (1) JP2005506981A (es)
KR (1) KR20040031053A (es)
AR (1) AR037233A1 (es)
BR (1) BR0212338A (es)
CA (1) CA2459527A1 (es)
HU (1) HUP0500131A3 (es)
IL (1) IL160716A0 (es)
MX (1) MXPA04002171A (es)
RU (1) RU2004110721A (es)
WO (1) WO2003022276A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000411A (es) * 2001-07-16 2004-03-18 Euro Celtique Sa Tiazolidinonas arilo sustituidas y uso de las mismas.
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN100369898C (zh) * 2002-02-12 2008-02-20 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
US7229993B2 (en) * 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
EP1532119A2 (en) * 2002-07-31 2005-05-25 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
WO2004084824A2 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EA200700099A1 (ru) 2004-07-23 2007-08-31 Пфайзер Инк. Производные пиридина
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
JP4159586B2 (ja) * 2006-08-03 2008-10-01 エヌイーシーコンピュータテクノ株式会社 情報処理装置および情報処理の高速化方法
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
KR200451955Y1 (ko) * 2008-05-09 2011-01-25 박영주 차량진입 방지대
CA2732806A1 (en) * 2008-08-04 2010-02-11 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8883785B2 (en) 2010-01-25 2014-11-11 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
AR083023A1 (es) 2010-09-17 2013-01-23 Purdue Pharma Lp Compuestos de piridina y una composicion farmaceutica que los comprende
EP2625169B1 (en) 2010-10-05 2015-03-25 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
WO2012085650A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
CA2844521A1 (en) 2011-08-30 2013-03-07 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PL2753606T3 (pl) 2011-09-02 2018-02-28 Purdue Pharma L.P. Pirymidyny jako blokery kanałów sodowych
AU2012321111A1 (en) * 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) * 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
US9143309B2 (en) * 2012-04-13 2015-09-22 Dominant Technologies, LLC Hopping master in wireless conference
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9637458B2 (en) 2013-03-04 2017-05-02 Jeffrey Lockman Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
EP2968307A4 (en) 2013-03-15 2017-01-04 Purdue Pharma LP Carboxamide derivatives and use thereof
JP6422498B2 (ja) 2013-08-26 2018-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ アザスピロ［４．５］デカン誘導体及びその使用
US9951056B2 (en) * 2013-09-30 2018-04-24 Beijing Innocare Pharma Tech Co., Ltd. Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
US9834543B2 (en) 2013-12-23 2017-12-05 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
WO2015123398A1 (en) 2014-02-12 2015-08-20 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP6386088B2 (ja) 2014-05-06 2018-09-05 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体及びその使用
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
WO2015192053A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
JP2017525777A (ja) * 2014-08-28 2017-09-07 エックス−ケム，インコーポレーテッド 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149109A (en) 1962-02-20 1964-09-15 Searle & Co Certain 4-trifluoromethyl-2-(oxy/thio) pyrimidines
FR1477021A (fr) 1965-04-21 1967-04-14 Ilford Ltd Matières photographiques
GB1121922A (en) 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
FR1536093A (fr) 1966-09-10 1968-08-09 Basf Ag Nouvelles amino-4-alcoylmercapto-6-triazines-s
US3631036A (en) 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
US3709888A (en) 1970-06-01 1973-01-09 Sandoz Ag Aryl-substituted-pyrido(2,3-d)pyrimidin-2-ones
US3660414A (en) 1970-06-01 1972-05-02 Sandoz Ag Certain 5-aryl-2-amino-nicotinonitriles
US3940404A (en) 1974-03-06 1976-02-24 The United States Of America As Represented By The Secretary Of The Army 2-Substituted phenyl-6-trifluoromethyl-4-pyridyl-carbinolamines
US3886167A (en) 1974-03-06 1975-05-27 Us Army 2-Aryl-6-trifluoromethyl-4-pyridylcarbinolamine antimalarials
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
US4133956A (en) 1977-07-27 1979-01-09 Eli Lilly And Company Preparation of benzoylureas
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
ES490122A0 (es) 1979-04-05 1981-04-01 Lilly Industries Ltd Procedimiento para preparar piranonas 5-sustituidas
JPS56104883A (en) 1980-01-25 1981-08-20 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4769462A (en) 1980-06-02 1988-09-06 American Cyanamid Co. Novel 2-carbamoylnicotinic and 3-quinolinecarboxylic acids and esters
GB2095240A (en) 1981-03-05 1982-09-29 Fujisawa Pharmaceutical Co Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
DE3239573A1 (de) * 1981-10-28 1983-05-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte picolinsaeuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
FR2527206B1 (fr) 1982-05-18 1986-12-05 Sandoz Sa Nouveaux derives de la 2(1h)-pyridinone, leur preparation et leur utilisation comme medicaments
EP0096657B1 (de) 1982-06-08 1989-04-05 Ciba-Geigy Ag 2-Phenyl-, 2-Naphthyl- und 2-Heterocyclylpyrimidine als Gegenmittel zum Schützen von Kulturpflanzen vor durch Herbizide verursachte phytotoxische Schäden
DE3323118A1 (de) * 1982-06-28 1984-01-12 National Research Corp., London Substituierte allylbenzylester von cyclopropan- und anderen carbonsaeuren
EP0123700A1 (de) 1983-04-27 1984-11-07 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Picolinsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
US4701208A (en) 1983-08-02 1987-10-20 American Cyanamid Company Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof
SU1790172A1 (ru) 1984-05-17 1995-05-10 Всесоюзный Государственный Научно-Исследовательский И Проектный Институт Химико-Фотографической Промышленности Бисчетвертичные соли пиридина в качестве активаторов спектральной сенсибилизации фотографических бромйодсеребряных эмульсий, содержащих анионные или катион-анионные цианины
DE3685840D1 (de) 1985-04-30 1992-08-06 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
US4962109A (en) 1985-12-23 1990-10-09 Imperial Chemical Industries Plc Insecticidally and acaricidally active pyrimidine esters and intermediates therefor
GB8531637D0 (en) 1985-12-23 1986-02-05 Ici Plc Pyrimidine derivatives
JPS6320234A (ja) 1986-07-11 1988-01-27 Daihatsu Motor Co Ltd 自動車の２輪・４輪駆動切換装置
PH23565A (en) 1986-09-05 1989-08-25 Sumitomo Chemical Co Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
GB8627059D0 (en) 1986-11-12 1986-12-10 Cookson Group Plc Substituted trialine derivatives
ZW21687A1 (en) 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
US5116989A (en) 1987-11-06 1992-05-26 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
US5084462A (en) 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0356672B1 (en) 1988-07-13 1993-04-07 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
EP0362578A1 (en) 1988-09-14 1990-04-11 E.I. Du Pont De Nemours And Company Treatment of cancer in mammals by concurrent administration of 4-quinoline carboxylic acid derivatives and interleukin-2
FI895821A0 (fi) 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
GB8918893D0 (en) 1989-08-18 1989-09-27 Wellcome Found Pharmacologically active cns compounds
US4968702A (en) 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
GB8906470D0 (en) 1989-03-21 1989-05-04 Cookson Group Plc Photopolymerisable composition
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0428628A1 (en) * 1989-06-12 1991-05-29 General Electric Company A laminar impressor for coating flat substrates
DE3940476A1 (de) 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5136080A (en) 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
US5403934A (en) 1990-03-12 1995-04-04 Burroughs Wellcome Co. Heterocyclic compounds
EP0446604A3 (en) 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
AU644016B2 (en) 1990-09-28 1993-12-02 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
AU640283B2 (en) 1990-10-25 1993-08-19 Ihara Chemical Industry Co. Ltd. Picolinic acid derivative, production thereof, and herbicide
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
GB9124578D0 (en) 1991-11-20 1992-01-08 Smithkline Beecham Plc Chemical compounds
DE4200323A1 (de) 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
TW237456B (es) 1992-04-09 1995-01-01 Ciba Geigy
JPH0776542A (ja) 1993-09-06 1995-03-20 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6057346A (en) 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
US5849758A (en) 1995-05-30 1998-12-15 American Cyanamid Company Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines
CZ290330B6 (cs) 1995-01-26 2002-07-17 American Cyanamid Company 2,6-Disubstituované pyridinové a 2,4-disubstituované pyrimidinové deriváty, způsob a meziprodukty pro jejich výrobu, jejich pouľití a herbicidní prostředky na jejich bázi a způsob potlačování růstu neľádoucích rostlin
US6008161A (en) 1995-05-30 1999-12-28 American Cyanamid Company Herbicidal 2-(hetero)aryloxy-6-arylpyridines and 2-aryl-4-(hetero) aryloxypyrimidines
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
EP0854721B1 (en) 1995-08-02 2001-10-24 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
BR9809288A (pt) 1997-04-22 2001-08-07 Cocensys Inc Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas
AU1818599A (en) 1997-12-12 1999-07-05 Abbott Laboratories Triazine angiogenesis inhibitors
WO1999031062A1 (fr) 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
EP1040103B1 (en) 1997-12-19 2007-03-14 Takeda Pharmaceutical Company Limited Anilide derivative, production and use thereof
TR200002225T2 (tr) 1998-01-28 2000-12-21 Shionogi & Co., Ltd Yeni trisiklik bileşimler
CA2352612A1 (en) 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
AU760983B2 (en) 1998-12-24 2003-05-29 Aventis Pharmaceuticals Inc. Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds
DE60044395D1 (de) 1999-03-26 2010-06-24 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
NZ520041A (en) 2000-01-20 2004-11-26 Eisai Co Ltd Novel piperidine compounds and drugs containing the same
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU2001245897B2 (en) 2000-03-24 2006-07-06 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
NZ521870A (en) 2000-03-31 2004-08-27 Euro Celtique S Aminopyridines and their use as anticonvulsants and sodium channel blockers
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6394753B1 (en) * 2001-02-07 2002-05-28 Hypro Corporation Flexible impeller removal and installation method
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US7229993B2 (en) 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof

Also Published As

Publication number Publication date
CA2459527A1 (en) 2003-03-20
RU2004110721A (ru) 2005-10-10
MXPA04002171A (es) 2004-07-23
US20030055088A1 (en) 2003-03-20
US7579367B2 (en) 2009-08-25
WO2003022276A1 (en) 2003-03-20
US20070010554A1 (en) 2007-01-11
US7105549B2 (en) 2006-09-12
IL160716A0 (en) 2004-08-31
EP1432419A1 (en) 2004-06-30
US7943643B2 (en) 2011-05-17
BR0212338A (pt) 2004-09-21
JP2005506981A (ja) 2005-03-10
US20100048626A1 (en) 2010-02-25
HUP0500131A2 (hu) 2005-05-30
KR20040031053A (ko) 2004-04-09
US20080194627A9 (en) 2008-08-14
HUP0500131A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
AR037233A1 (es) Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR029489A1 (es) Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2400778A1 (en) Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
MX2022014458A (es) Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
NZ334613A (en) Pharmaceutical agents comprising Rho kinase inhibitor
IL108562A (en) 7, 8-diaryl-1,2,3,4- terahydropyrazolo- £5,1-c| £1,2,4| triazine derivatives, methods for the preparation thereof and pharmaceutical compositions containing them
MXPA01009655A (es) Pirazoles, imidazoles, oxazoles, tiazoles y pirroles substituidos con arilo y uso de los mismos.
LTIP846A (en) N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2h-benzopyran)carboxamide derivatives,processes for the preparation thereof and pharmaceutical compositions
RU2006147307A (ru) Производные 3-карбамоил-2-пиридона
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
HUP0401819A2 (hu) Proteinkináz inhibitorokként alkalmazható pirazolvegyületek és ezeket tartalmazó gyógyszerkészítmények
NO933452L (no) Et terapeutisk middel for Parkinson's sykdom
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
ES8505972A1 (es) Un procedimiento para preparar derivados de pirimidina
HRP20080119T3 (en) Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
IL79841A0 (en) Heterocyclic compounds,their production and pharmaceutical compositions containing them
RS111104A (en) 1-/(indol-3-yl)carbonyl/piperazine derivatives
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
BRPI0409374A (pt) composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico
MXPA05010651A (es) Compuestos de pirazol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure